Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expression

7 Aug 2023

Abstract excerpt

Cancer immunotherapies, in particular checkpoint blockade immunotherapy (CBT), can induce control of cancer growth, with a fraction of patients experiencing durable responses. However, the majority of patients currently do not respond to CBT and the molecular determinants of resistance have not been fully elucidated. Mounting clinical evidence suggests that the clonal status of neoantigens (NeoAg) impacts the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to CAR-T cell therapy research
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37548358
DOI: 10.7554/elife.85263

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Decoupled neoantigen cross-presentation by dendritic cells limits anti-tumor immunity against tumors with heterogeneous neoantigen expressionPMID 37548358Read ↗

Decoupled neoantigen cross-presentation in tumors with high intratumor heterogeneity reduces dendritic cell activation to limit anti-tumor immunitySemantic proximity Read ↗

Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.Semantic proximity Read ↗

DC targeted therapy breaks immune tolerance against neoantigens in refractory lung adenocarcinomaSemantic proximity Read ↗

Integrated modeling to implicate evolving neoantigen-T cell interplays and immunotherapy efficacy in tumorsSemantic proximity Read ↗

A novel integrated approach to predicting cancer immunotherapy efficacySemantic proximity Read ↗

Tumor Neoantigens: When Too Much of a Good Thing Is Bad.Semantic proximity Read ↗

The Current Lung Cancer Neoantigen Landscape and Implications for Therapy.Semantic proximity Read ↗

Boosting Antitumor Immunity with an Expanded Neoepitope Landscape.Semantic proximity Read ↗

An Empirical Antigen Selection Method Identifies Neoantigens That Either Elicit Broad Antitumor T-cell Responses or Drive Tumor Growth.Semantic proximity Read ↗

Harnessing neoantigen specific CD4 T cells for cancer immunotherapySemantic proximity Read ↗

Cancer Neoantigen Vaccines Emerge Efficacious.Semantic proximity Read ↗

Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.